6CM
ARMP icon

683 Capital Management’s Armata Pharmaceuticals ARMP Stock Holding History

683 Capital Management’s Portfolio ARMP Stock Details ARMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.4M Sell
137,000
-2,860
-2% -$24.1K 0.07% 127
2025
Q4 		$878K Buy
+139,860
New +$766K 0.04% 153

Other funds holding ARMP

MAM
Madison Asset Management Madison, Wisconsin $8.06B AUM 11.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

683 Capital Management's ARMP Position: Q1 2026 in Review

683 Capital Management reduced its Armata Pharmaceuticals (ARMP) stake by 2% in Q1 2026, selling an estimated $24.1K and leaving 137,000 shares worth $1.4M. The position accounts for 0.07% of the portfolio, ranked #127.

683 Capital Management first reported a position in ARMP in Q4 2025 and has held it in 2 quarters since. 45 funds tracked by Wall St. Rank hold ARMP as of Q1 2026.

  • 683 Capital Management held 137,000 shares of Armata Pharmaceuticals worth $1.4M as of Q1 2026.
  • 683 Capital Management sold 2,860 Armata Pharmaceuticals shares in Q1 2026, an estimated $24.1K.
  • Armata Pharmaceuticals made up 0.07% of 683 Capital Management's portfolio in Q1 2026, its #127 holding.
  • 683 Capital Management first reported a position in Armata Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 45 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.